Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antivenin latrodectus equine immune F(ab')2
- Development stage
- Unknown
- Lead developer
- Instituto Bioclon
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Antivenin latrodectus equine immune F(ab')2 is an investigational antivenom composed of **purified F(ab')2 antibody fragments** derived from serum of horses hyperimmunized against *Latrodectus* (black widow) spider venom. The F(ab')2 fragments are generated by enzymatic cleavage (pepsin digestion) of equine immunoglobulin to reduce the risk of allergic reactions associated with whole IgG preparations[1]. The preparation neutralizes black widow spider venom toxins and is intended for intravenous use in the management of moderate to severe symptoms of latrodectism, such as systemic pain and myopathic syndrome[1][2][6]. Clinical trials indicate it is effective at reducing pain and treatment failures compared to placebo, with a favorable safety profile[1][2][6].
- Brand names
- Analatro
- Other names
- black widow antivenom F(ab')2black widow spider antivenin F(ab')2
Beyond the preview
Go deeper on antivenin latrodectus equine immune F(ab')2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antivenin latrodectus equine immune F(ab')2.